Navigation Links
Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference
Date:2/2/2012

KALAMAZOO, Mich., Feb. 2, 2012 /PRNewswire/ -- On February 2, at the Late-Breaking Science Session at the International Stroke Conference, Stryker announced the results of the TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke). This was one of the first prospective, multi-center clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centers in Europe.

(Logo:  http://photos.prnewswire.com/prnh/20120202/NY46927LOGO )

The TREVO Study was designed to assess the ability of the Trevo® System to remove the blood clots that cause strokes and to restore blood flow to the brain. Revascularization was measured by an independent core lab.

The results were presented at the International Stroke Conference in New Orleans, LA by Professor Nils Wahlgren, co-Principal Investigator of the Study and Professor of Neurology at Karolinska University Hospital, Solna, Sweden. The results demonstrated high revascularization rates of 91.7% of patients. 46% of patients achieved a good outcome in just seven days and at 90 days, the good outcomes rate increased to 55%. These patients with good outcomes were functionally independent (modified Rankin score of 2 or less). A low symptomatic intracranial hemorrhage rate of 5% was also reported.

Professor Wahlgren commented: "The TREVO Study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes that can be achieved for these patients."

Clinical evidence remains key for wider adoption of interventional, device-based therapies for the treatment of Acute Ischemic Stroke. The prospective design and rigorous conduct of the TREVO Study underscores Stryker's commitment to building robust evidence to support the adoption of important technologies like the Trevo System by physicians for their stroke patients.

About Stryker

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

Media Contact:
Tamara Cutler
Vice President, Public Affairs
269-389-7253
tamara.cutler@stryker.com


'/>"/>
SOURCE Stryker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STRYKER Signs Definitive Agreement to Acquire CONCENTRIC MEDICAL, Inc.
2. Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform
3. Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms
4. Stryker Ends Distribution Agreement With Corin PLC
5. Stryker Announces Exclusive Collaboration With RegenLab
6. Stryker Launches VersiTomic G-Lok™
7. Stryker Orthopaedics Launches Its First iPad™ Apps for Surgeons, Available Through Apples App Store(SM)
8. Stryker Features Tissue-Preservation Hip Arthroscopy Platform, Sponsors Surgeon Education Events at the AAOS Annual Meeting
9. Fred Funk Becomes Spokesperson for Stryker Orthopaedics
10. Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System
11. Stryker Declares a $0.18 Per Share Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the ... Cosmetic dentistry is a fast-growing field as more patients are discovering the many different ... more about the options currently available to them and which ones might work for ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... ... 2016 , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. ... Potter -- are proud of the recent release of their 2014 in vitro fertilization ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows ...
Breaking Medicine News(10 mins):